ArticleInternational journal of dermatology2026
Skin Cancer Predisposition Genes, Full-Body Skin Examinations, Familial Disclosure, and Genetic Testing Among High-Risk Individuals.
Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Skin Cancer Predisposition Genes, Full-Body Skin Examinations, Familial Disclosure, and Genetic Testing Among High-Risk Individuals.International journal of dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThere is a lack of knowledge in full-body skin examinations (FBSEs) in the context of pathogenic or likely pathogenic variants (PV/LPV) in skin cancer predisposition genes (CPGs). This study assessed the association between carrier status of PV/LPV in skin CPGs and FBSEs and described the patterns of family letter receipt, familial disclosure, and cascade testing among high-risk individuals.
methodsBetween July and September 2023, we surveyed participants enrolled in the Chicago Cancer Prone Study. Carrier status of PV/LPV in skin CPGs was defined as having been told by a genetic counselor that they have a PV/LPV in CDKN2A, TP53, PTEN, BRIP1, PALB2, ATM, and/or CHEK2 genes. FBSEs were assessed by asking individuals whether they ever had an FBSE and modeled using logistic regression.
resultsOf 579 individuals (mean age, 59.5 years), 11.6% carry PV/LPV in skin CPGs and 63.8% ever had a FBSE. Carriers had greater odds of FBSEs than non-carriers (adjusted odds ratio, 2.15; 95% CI, 1.03-4.52). White race, older age, and female sex were associated with increased odds of FBSEs. Among carriers, 65.3% received a family letter from their genetic counselor after testing; 91.0% disclosed their PV/LPV-carrying status to any family members, and 62.7% of the individuals' family members underwent genetic testing.
conclusionsWe found greater odds of FBSEs among PV/LPV carriers, notable disparities in FBSEs, and prevalent family letter receipt, familial disclosure, and cascade testing. This study highlights the role of PV/LPV-carrying status on FBSEs and the potential need for comprehensive guidelines beyond known risk factors to optimize skin cancer screening in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.